Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 6—June 2021
Dispatch

Ebola Virus IgG Seroprevalence in Southern Mali

Sidy Bane, Kyle Rosenke, Ousmane Maiga, Friederike Feldmann, Kimberly Meade-White, Julie Callison, David Safronetz, Nafomon Sogoba, and Heinz FeldmannComments to Author 
Author affiliations: University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali (S. Bane, O. Maiga, N. Sogoba); National Institutes of Health, Hamilton, Montana, USA (K. Rosenke, F. Feldmann, K. Meade-White, J. Callison, H. Feldmann),; Public Health Agency of Canada, Winnipeg, Manitoba, Canada (D. Safronetz)

Main Article

Table

Results of EBOV serology on 600 human samples from southern Mali*

Location No. (%) positive
EBOV GP IgG
 EBOV NP IgG
 Both
1:100 1:400 1:1,600 1:100 1:400 1:1,600 1:100 1:400 1:1,600
Bamba 23 (11.5) 2 (1.0) 0 ND 6 (3.0) 2 (1.0) NA 1 (0.5) 0
Banzana 39 (19.5) 9 (4.5) 1 (0.5) ND 5 (2.5) 0 NA 2 (1.0) 0
Soromba
 60 (30.0)
 11 (5.5)
 0
ND
 13 (6.5)
 2 (1.0)
NA
 6 (3.0)
 0
Total 122 (20.3) 22 (3.7) 1 (0.2) ND 24 (4.0) 4 (0.7) NA 9 (1.5) 0

*A total of 200 samples were tested from each location. EBOV, Ebola virus; GP, glycoprotein. NA, not applicable; ND, not done; NP, nucleoprotein.

Main Article

Page created: April 21, 2021
Page updated: May 18, 2021
Page reviewed: May 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external